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Abstract
We investigated the presence of qnrC and qnrD among 756 non-
replicate Enterobacteriaceae isolated in Italy, selected for being
non-susceptible to ﬂuoroquinolones and/or resistant to third-
generation cephalosporins. Four Proteus mirabilis and one Morga-
nella morganii (0.66% of the total) presented a qnrD gene, located
in a 2687-base-pair plasmid that was entirely sequenced. The
plasmid is un-typable, and contains no known coding region
other than qnrD. That the qnrD gene was found in four unre-
lated P. mirabilis and in one M. morganii isolate might suggest a
frequent association of this gene with the tribe Proteeae.
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Plasmid-mediated quinolone resistance caused by the pro-
duction of pentapeptide repeat proteins, encoded by qnr
determinants, has been described in Enterobacteriaceae clinical
isolates worldwide [1]. To date, six qnr determinants have
been detected and studied, namely qnrA [2], qnrB [3], qnrS
[4], qnrC [5] and qnrD [6] and qnrVC [7]. The qnrD gene was
ﬁrst described in 2009 on a 4270-base-pair (bp) plasmid
present in a human clinical isolate of Salmonella enterica ser-
ovar Kentucky and three Salmonella enterica serovar Bovi-
smordiﬁcans isolates from China [6]. In 2010, one Escherichia
coli isolated from swine in China [8], one Morganella morganii
in Algeria (20th European Congress of Clinical Microbiology
and Infection Diseases abstract O558), and two Proteus mira-
bilis and one Pseudomonas aeruginosa in Nigeria [9], all iso-
lated from human clinical specimens, were found to be
positive for this determinant.
In 2010 our group produced a brief report on the ﬁrst
qnrD determinants in Europe, found in four P. mirabilis and
one M. morganii clinical isolates [10], and the occurrence in
Europe of qnrD-positive S. enterica isolates has been subse-
quently cited [11].
The present report deals with the full characterization of
the qnrD gene found in the European isolates of Proteeae and
of the harbouring plasmid.
In all, 756 non-replicate Enterobacteriaceae strains were
collected over the period 2007–2008 from the Hospital Lab-
oratories of Bolzano, Rovereto, Trento, Verona and Vicenza,
all from north-eastern Italy. Specimens included in the study
were from inpatients admitted to either hospitals or long-
term care facilities, and from outpatients. All isolates col-
lected had MICs for ciproﬂoxacin and levoﬂoxacin ‡0.25 mg/
L) and/or resistant to third-generation cephalosporins
(according to the EUCAST breakpoints, http://www.eu-
cast.org/clinical_breakpoints/ version 1.1).
The collection included 497 E. coli, 69 Proteus spp., 52
Enterobacter spp., 68 Klebsiella spp., 24 M. morganii, 18 Citrob-
acter spp., 21 Providencia spp. and seven Serratia spp.
All strains were screened for the presence of qnrC [5] and
qnrD [6]; they were also screened for qnrA, qnrB and qnrS (by
multiplex PCR [12]) and for other plasmid-mediated quino-
lone resistance determinants, namely aac(6¢)-Ib [13] and qepA
[14] (by using primers and conditions as previously published).
Five isolates from urinary tract infections (0.66%), namely
four P. mirabilis (three isolates from Verona and one from
Trento) and one M. morganii (from Verona), presented a
qnrD gene, but no isolate was positive for any of the other
determinants.
The MICs for the qnrD-positive strains were 1024 mg/L
for nalidixic acid, between 1 and 4 mg/L for ciproﬂoxacin,
and between 2 and 8 mg/L for levoﬂoxacin. Susceptibility
tests were performed by broth microdilution and interpreted
with the latest EUCAST criteria (http://www.eucast.org/
clinical_breakpoints/ version 1.1).
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Positive PCR products were puriﬁed using a QIAquick
PCR Puriﬁcation Kit (Qiagen, Hilden, Germany) and
sequenced on both strands (Euroﬁns MWG Operon, Ebers-
berg, Germany). The DNA sequences obtained were aligned
at NCBI BLAST and showed 100% similarity with the ﬁrst qnrD
gene described by Cavaco et al. [6].
Plasmid extraction from all the qnrD-positive clinical isolates
was performed by QIAprep Spin Miniprep Kit (Qiagen) and
treated with Plasmid-Safe ATP-dependent DNase (Epicentre
Technologies, Madison, WI, USA) to remove contaminating
chromosomal DNA. Plasmids were run onto 0.8% (weight/vol-
ume) agar gel at 60 V for 60 min; the gels were stained with
ethidium bromide and showed a c. 3 kilobase plasmid common
to all isolates. The DNA was transferred to a nylon membrane
(Roche, Mannheim Germany) and Southern blot analysis was
performed by standard methods [15]. The qnrD-speciﬁc probe
was synthesized using PCR by incorporating digoxigenin-11-
dUTP (Roche) into the product by using the qnrD primers. In
all ﬁve cases, the probe reacted with the membrane at the
level of c. 3 kilobases, hence it was possible to demonstrate a
plasmidic localization for the qnrD gene in all cases (Fig. 1).
Plasmid incompatibility groups were determined by a
PCR-based replicon typing method also with the extend
scheme as previously described [16,17], and the plasmid
proved un-typable.
The whole sequence of the plasmid harbouring the qnrD
gene was obtained by PCR walking. First, we used comple-
mentary and anti-parallel oligonucleotides of qnrDfw and
qnrDrev, namely: INVDF/R: 5’-TATTCCCCGTAAATTGA-
TCTCG-3’ and INVDR/F: 5’-CAGGCGCTTCAGCTTGTT-3’,
with the following thermal proﬁle: one cycle at 95C for
2 min, 30 cycles of 94C for 30 s, 53C for 30 s, 72C for
3 min with a ﬁnal elongation of 72C for 10 min and 4C to
close the reaction. A 2200 bp PCR product was obtained.
The whole sequences of P. mirabilis (2687 bp) and M. morga-
nii (2864 bp) qnrD plasmids were deposited at GenBank with
accessions numbers JN183060 and JN183061, respectively.
In the whole plasmid sequence we could recognize the
qnrD gene and its promoter, showing 100% identity
between all ﬁve strains and between them and the previ-
ously described qnrD-harbouring plasmid [6]. Besides the
qnrD gene, our plasmid also shows an open-reading frame
with 96% homology with Orf2, present in the published
plasmid FJ228229 [6] and coding for a putative protein
FJ228229.
Sequencing of the Quinolone Resistance Determinant
Regions (QRDRs) of gyrA, gyrB, parC and parE was carried
out in P. mirabilis qnrD-positive strains. The gyrA gene QRDR
sequencing in P. mirabilis was carried out with the following
primers, designed in this study: gyrA Proteus Fw:
TGCCAGAGAAATCACACCAG and gyrA Proteus Rev:
TTTCCAAATCCGCCAGCAG and the following conditions:
one cycle at 95C for 5 min, 35 cycles of 95C for 1 min,
52C for 1 min, 72C for 1 min and one cycle at 72C for
10 min. The gyrB, parC and parE QRDRs were investigated
using primers and conditions as previously reported [18].
The same mutation at codon 83 of gyrA (S83I) was found in
all P. mirabilis strains. Mutations were also found in the QRDR
of parC at codon 80. In three cases it was an S80I substitution,
and in one case an S80R substitution. These mutations may
contribute to the ﬂuoroquinolone-resistance level in these
strains. No other mutations were found in other genes.
No complete genome or QRDRs are available for M. mor-
ganii to design a primer, so we performed PCR experiments
using a consensus primer designed for Enterobacteria [19].
However, we never obtained a PCR product to sequence,
even using a very low annealing temperature.
To investigate the clonal relationship between the four
P. mirabilis qnrD-positive strains, we performed a random
ampliﬁed polymorphic DNA technique with the previously
described primers Opa11, Opx13, Opz08 and thermal proﬁle
[20]. The ampliﬁcation mixture (50 lL) contained 1 unit Taq
(5’), 45 mM KCl, 2.5 mM Mg2+, 200 lM, each dNTP, 4 lM
primer, 3 lL DNA.
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FIG. 1. Southern blot (left) and corresponding plasmid proﬁles (right) of the ﬁve qnrD-positive strains. Each strain was running as untreated (a)
and treated to remove any trace of chromosome DNA (b). 1: qnrD gene; 2a, 2b: Proteus mirabilis strain T80; 3a, 3b: P. mirabilis strain VR67; 4a,
4b: P. mirabilis strain VR758; 5a, 5b: P. mirabilis strain VR1048; 6a, 6b: Morganella morganii VR831.
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All four P. mirabilis strains showed a different random
ampliﬁed polymorphic DNA proﬁle. They were not corre-
lated with one another and the highest discrimination results
were obtained with Opx13 (Fig. 2).
This is the ﬁrst report of a qnrD gene in the Proteeae tribe
in Europe. We found the qnrD gene in four different P. mira-
bilis and in one M. morganii isolate, but not in any other
species of the large Enterobacteriaceae collection investigated.
Proteus and Morganella had also accounted for three of the
ﬁve isolates previously described outside Europe, so a fre-
quent association of qnrD with the tribe Proteeae might be
hypothesized. This is a concern in view of the frequent isola-
tion of Proteeae strains among elderly patients, often carrying
a urinary catheter, and of the common use of quinolones for
treating urinary tract infections in these patients.
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FIG. 2. Random ampliﬁed polymorphic DNA proﬁle of four qnrD-
positive Proteus mirabilis with primer Opx13. M: Marker; 1: strain
T80; 2: strain VR67; 3: strain VR758; 4: strain VR1048.
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